These days, early stage investors — who are almost always angel investors and not venture capital funds — want more of their funding to go toward proving market feasibility and less to be spent on building risky prototypes.
These first investors are increasingly looking for deal flow with mitigated product development risk, especially in bioscience and advanced manufacturing startups where the product development time and costs to prove regulatory milestones or alpha and beta trials are significantly greater than in other industries.
